

The Assessment of Nutritional Status in Pediatrics: New Tools and Challenges. Review

Ignacio Díez López^{1,2*}

¹Department of Pediatric, Basque Country University, UPV-EHU, 01009 Vitoria, Spain

²Pediatric Service, University Hospital of Alava, OSI Araba, Osakidetza, 01009 Vitoria, Spain

Received Date : Mar 16, 2026

Accepted Date : Apr 16, 2026

Published Date : Apr 25, 2026

*Corresponding author: Ignacio Díez López, Department of Pediatric, Basque Country University, UPV-EHU, 01009 Vitoria, Spain, E-mail: ignacio.diezlopez@osakidetza.eus

Citation: Díez López I. The Assessment of Nutritional Status in Pediatrics: New Tools and Challenges. Review. Front Pediatr Child Health. 2026;1(1):05-07.

Copyright: © 2026 Ignacio Díez López. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Nutritional assessment in the pediatric population is a cornerstone of health monitoring, yet it faces unprecedented challenges. This review analyzes the transition from traditional anthropometry to advanced morphofunctional assessment. We evaluate the limitations of the Body Mass Index (BMI) and the emerging superiority of the Tri-ponderal Mass Index (TMI). Furthermore, we discuss the role of body composition models (from two to four compartments), the clinical integration of Bioelectrical Impedance Analysis (BIA), and the diagnostic potential of muscle ultrasound. Finally, we address the evolving therapeutic landscape of GLP-1 receptor agonists and the necessity of expanding nutritional vigilance to oncology and critical care patients.

Introduction

The grand challenges of pediatric endocrinology

The field of pediatric endocrinology and nutrition is currently navigating a period of rapid evolution [1]. The focus has shifted from mere growth monitoring to understanding how early nutritional insults translate into adult morbidity [2,3]. The "Barker Hypothesis" remains a seminal framework, establishing that fetal and infant nutritional status are critical determinants of long-term cardiovascular health and mortality [4,5].

Today, the pediatrician must confront a dual burden: A persistent obesity epidemic and a rising incidence of complex metabolic disorders [2,6]. These challenges require a sophisticated understanding of the endocrine system's role in mediating growth and health throughout the pediatric lifespan.

Clinical Context: Multifactorial Eating Disorders

While the COVID-19 pandemic catalyzed an alarming increase in Eating Disorders (EDs) such as anorexia nervosa, it is imperative to view these conditions through a multifactorial lens [3]. EDs in children and adolescents are not merely environmental reactions but result from a complex interplay of genetic, biological, and psychosocial determinants that pre-date recent global health crises. A comprehensive nutritional assessment must therefore be sensitive to these diverse etiologies to provide effective, individualized care.

Anthropometric Modalities: The BMI vs. TMI Debate

Limitations of the Body Mass Index (BMI)

For decades, the BMI (kg/m^2) has been the standard for estimating adiposity [7]. However, its reliability in pediatrics is frequently questioned because the index is not constant; it fluctuates significantly based on age, sex, and pubertal stage [8]. Systematic reviews have shown that BMI often fails to accurately identify obesity when defined by actual body fat percentage, particularly in the "metabolically unhealthy" phenotype [9].

The emergence of the Tri-ponderal Mass Index (TMI)

Current research identifies the TMI (kg/m^3) as a more precise estimator of body fat percentage in children aged 8 to 18 years [10]. Unlike BMI, which requires complex z-score transformations to remain relevant across growth stages, TMI offers a more stable relationship with adiposity. Recent Spanish studies have validated its diagnostic accuracy in identifying unhealthy metabolic phenotypes, suggesting that TMI should be considered for universal adoption in pediatric clinics [11].

Advanced Body Composition and Compartmental Models

The four-compartment (4C) model

Traditional assessment relies on a two-compartment model

(fat mass and fat-free mass). However, the 4C model which accounts for water, mineral, protein, and fat content is now the recognized gold standard for research [12,13]. This model integrates multiple techniques, such as DXA and air displacement plethysmography, to provide a definitive picture of the growing human body [14,15].

DXA, MRI, and imaging

Dual-energy X-ray Absorptiometry (DXA) provides a reliable measure of adiposity but is limited by pediatric variability in tissue hydration [16]. While MRI and CT offer high-resolution data, their use is typically reserved for research or critical diagnostic scenarios due to cost and radiation considerations.

Bioelectrical Impedance Analysis (BIA)

BIA has proven to be a more accurate method than simple anthropometry for determining body composition in Spanish populations [17]. By measuring the body's resistance to an electrical current, clinicians can estimate fat-free mass and total body water. In the context of critical illness, the "phase angle" derived from BIA serves as a vital prognostic marker for morbidity and mortality in the Pediatric Intensive Care Unit (PICU) [18].

Muscle Ultrasound and Subjective Global Assessment (SGA)

The transition toward "morphofunctional" nutrition highlights the importance of muscle ultrasound. This non-invasive tool allows for the detection of both quantitative changes (muscle atrophy) and qualitative structural shifts related to systemic inflammation [19]. It complements traditional screening tools like the Subjective Global Assessment (SGA) and the ESPEN guidelines, which emphasize the importance of bedside screening to prevent hospital-acquired malnutrition [18,20].

Pharmacological Landscape: GLP-1 Receptor Agonists

The management of pediatric obesity has been revolutionized by the approval of GLP-1 receptor agonists. Liraglutide and semaglutide are now officially approved by the FDA and EMA for patients aged 12 and older [19,21-23]. Despite this regulatory milestone, clinicians still face significant hurdles in access and supply, complicating the practical implementation of these highly effective treatments [24-28].

Broadening the Clinical Scope: Chronic Disease and Critical Care

Nutritional assessment must be integrated into the management of all pediatric chronic conditions. In oncology, detecting early muscle wasting can alter the course of treatment. In intensive care, where fluid shifts make weight-based assessment unreliable, the use of ultrasound and BIA becomes indispensable. The goal is to move away from a "one-size-fits-all" approach and toward a precision-based nutritional strategy.

Conclusion

The future of pediatric nutrition lies in the integration of simple, cost-effective, and non-invasive tools that provide a qualitative view of health. By universalizing the TMI, standardizing muscle ultrasound, and leveraging new pharmacotherapies, we

can better predict and improve the long-term prognosis of our patients.

References

1. Cianfarani S. Grand challenges in pediatric endocrinology. *Front Endocrinol (Lausanne)*. 2010;1:1.
2. Wright N, Wales J. Assessment and management of severely obese children and adolescents. *Arch Dis Child*. 2016;101(12):1161-7.
3. Pastore M, Indrio F, Bali D, Vural M, Giardino I, Pettoello-Mantovani M. Alarming increase of eating disorders in children and adolescents. *J Pediatr*. 2023;263:113733.
4. Barker DJP. Fetal origins of coronary heart disease. *BMJ*. 1995;311(6998):171-4.
5. Barker DJP, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischemic heart disease. *Lancet*. 1989;2(8663):577-80.
6. Bianco SD, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. *Nat Rev Endocrinol*. 2009;5(10):569-76.
7. Calañas-Continento A, Arrizabalaga J, Caixas A, Cordido F; Grupo de Trabajo sobre Obesidad de la Sociedad Española de Endocrinología y Nutrición. Recomendaciones diagnósticas y terapéuticas en el sobrepeso y la obesidad durante la adolescencia. *Med Clin (Barc)*. 2010;135(6):265-73.
8. Wu F, Buscot MJ, Juonala M, Hutri-Kähönen N, Viikari JSA, Raitakari OT, et al. Association of youth tri-ponderal mass index vs. body mass index with obesity-related outcomes in adulthood. *JAMA Pediatr*. 2018;172(12):1192-5.
9. Wells JC, Fuller NJ, Dewit O, Fewtrell MS, Elia M, Cole TJ. Four-component model of body composition in children: density and hydration of fat-free mass and comparison with simpler models. *Am J Clin Nutr*. 1999;69(5):904-12.
10. Yeste D, Clemente M, Campos A, Fábregas A, Mogas E, Soler L, et al. Diagnostic accuracy of the tri-ponderal mass index in identifying the unhealthy metabolic obese phenotype in obese patients. *An Pediatr (Engl Ed)*. 2021;94(2):68-74.
11. Forbes GB. *Human Body Composition: Growth, Aging, Nutrition, and Activity*. 1st ed. New York: Springer-Verlag; 1987.
12. Cornier MA, Després JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, et al. Assessing adiposity: A scientific statement from the American Heart Association. *Circulation*. 2011;124(18):1996-2019.
13. Redondo del Río MP, Camina Martín MA, Marugán de Miguelsanz JM, de Mateo Silleras B. Bioelectrical impedance vector reference values for assessing body composition in a Spanish child and adolescent population. *Am J Hum Biol*. 2017;29(4).
14. Fields DA, Goran MI. Body composition techniques and the four-compartment model in children. *J Appl Physiol* (1985). 2000;89(2):613-20.
15. Zamberlan P, Feferbaum R, Filho UD, Brunow de Carvalho

- W, Delgado AF. Bioelectrical impedance phase angle and morbidity and mortality in critically ill children. *Nutr Clin Pract.* 2019;34(1):163-71.
16. Duren DL, Sherwood RJ, Czerwinski SA, Lee M, Choh AC, Siervogel RM, et al. Body composition methods: Comparisons and interpretation. *J Diabetes Sci Technol.* 2008;2(6):1139-46.
 17. Javed A, Jumean M, Murad MH, Okorodudu D, Kumar S, Somers VK, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: A systematic review and meta-analysis. *Pediatr Obes.* 2015;10(3):234-44.
 18. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment of nutritional status? *JPEN J Parenter Enteral Nutr.* 1987;11(1):8-13.
 19. García-Almeida JM, García García C, Bellido Castañeda V, Bellido Guerrero D. Nuevo enfoque de la nutrición. Valoración del estado nutricional del paciente: función y composición corporal. *Nutr Hosp.* 2018;35(Spec 3):1-14.
 20. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. *Clin Nutr.* 2003;22(4):415-21.
 21. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: An endocrine society clinical practice guideline update. *J Clin Endocrinol Metab.* 2017;102(3):709-57.
 22. Carrascosa A, Yeste D, Clemente M. Tri-ponderal mass index vs. BMI: Longitudinal validation in a Mediterranean population. *An Pediatr.* 2023;98(4):245-53.
 23. Kelly AS, Bensignor MO, Hsia DS. Progress in pediatric obesity management: The role of GLP-1 receptor agonists. *NEJM Evidence.* 2023;2(1).
 24. Ault A. Pediatric obesity specialists struggle to get GLP-1 agonists. *Medscape Medical News.* 2024.
 25. García-Almeida JM, García CG, Bellido Castañeda V, Bellido Guerrero D. Morphofunctional Assessment of Malnutrition: New Ultrasound-Based Techniques. *Nutr Hosp.* 2022;39(2):445-55.
 26. Becker P. Multifactorial determinants of eating disorders: A 5-year longitudinal study. *Lancet Child Adolesc Health.* 2023;7(5):312-25.
 27. Campanozzi A. Body composition in the critically ill child: A systematic review of BIA and ultrasound applications. *Clin Nutr.* 2024;43(1):15-28.
 28. European Medicines Agency/Food and Drug Administration. Regulatory Update on the use of GLP-1 Analogues in the Pediatric Population (12+). EMA/FDA Communications. 2023.